TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
9.45
+0.23 (2.49%)
At close: Nov 28, 2025, 1:00 PM EST
9.34
-0.11 (-1.16%)
After-hours: Nov 28, 2025, 4:01 PM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change (1Y)
-3
Growth (1Y)
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,876,275
Market Cap
8.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7 | -3 | -30.00% |
| Dec 31, 2023 | 10 | -9 | -47.37% |
| Dec 31, 2022 | 19 | 10 | 111.11% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RNAZ News
- 12 days ago - TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - PRNewsWire
- 6 weeks ago - TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - PRNewsWire
- 6 months ago - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - PRNewsWire
- 7 months ago - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - PRNewsWire
- 7 months ago - TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split - PRNewsWire
- 7 months ago - TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - PRNewsWire
- 7 months ago - TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer - PRNewsWire
- 7 months ago - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting - PRNewsWire